Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fusion AntibodiesLSE:FAB -21.28% Equity-to-Asset is 0.40 as of Sep. 2025, which is 49% below its 10-year median of 0.79. The stock has 4 warning signs investors should review. Among 1,412 Biotechnology companies, Fusion Antibodies ranks worse than 73.87% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Fusion Antibodies's Total Stockholders Equity for the quarter that ended in Sep. 2025 was £0.73 Mil. Fusion Antibodies's Total Assets for the quarter that ended in Sep. 2025 was £1.81 Mil.
Therefore, Fusion Antibodies's Equity to Asset Ratio for the quarter that ended in Sep. 2025 was 0.40.
The historical rank and industry rank for Fusion Antibodies's Equity-to-Asset or its related term are showing as below:
LSE:FAB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.4 Med: 0.79 Max: 0.91
Current: 0.4
During the past 11 years, the highest Equity to Asset Ratio of Fusion Antibodies was 0.91. The lowest was 0.40. And the median was 0.79.
LSE:FAB's Equity-to-Asset is ranked worse than 73.87% of 1412
companies
in the Biotechnology industry
Industry Median: 0.69
vs LSE:FAB: 0.40
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Fusion Antibodies Equity-to-Asset Related Terms
Fusion Antibodies Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FAB vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Fusion Antibodies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Fusion Antibodies's Equity to Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a Equity-to-Asset of 0.40 as of Sep. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Fusion Antibodies and its competitors. This is 49% below median its historical median of 0.79. Over the past decade, Fusion Antibodies' Equity-to-Asset has ranged from 0.40 to 0.91. According to the industry distribution chart, Fusion Antibodies ranks #1043 out of 1412 companies in the Biotechnology industry, placing it in the top 73.9%.
Is Fusion Antibodies' Equity-to-Asset too high?
Fusion Antibodies' current Equity-to-Asset of 0.40 is 49% below median its 10-year median of 0.79. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 0.91. The Biotechnology industry median Equity-to-Asset is 0.69. Fusion Antibodies' value of 0.40 is 42% below this industry median. Based on the distribution chart, Fusion Antibodies ranks #1043 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint.
How does Fusion Antibodies' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #1043 out of 1412 companies for Equity-to-Asset. This places Fusion Antibodies in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Fusion Antibodies' value of 0.40 is 42% below this benchmark. Historically, Fusion Antibodies' own Equity-to-Asset has ranged from 0.40 to 0.91 over the past decade. While the company's 10-year median is 0.79 vs. the industry median of 0.69, Fusion Antibodies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fusion Antibodies's current Equity-to-Asset of 0.40 is 42% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Fusion Antibodies and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current Equity-to-Asset is 0.40, which is 49% below median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.09 — trading 131.3% above its estimated fair value. The current Equity-to-Asset is 0.40, which is 49% below median its 10-year median of 0.79 and 42% below the Biotechnology industry median of 0.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Equity-to-Asset is 0.40 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
